How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,537 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Zinc-MNP Trial for Prevention of Diarrhea and Promotion of Linear Growth

of a placebo powder for 24 weeks. Outcome Measures Go to Primary Outcome Measures : Incidence of diarrhea [ Time Frame: Incidence over the 24-week follow-up period ] Incidence of diarrhea is defined as the number of diarrheal episodes per person-weeks of follow-up Change in length-for-age Z score [ Time Frame: Measured at enrollment and the end of the 24-week follow-up period ] Change in length-for-age Z score from enrollment to the end of the 24-week follow-up period Secondary Outcome Measures : Change (...) to support growth in young children especially for tissues undergoing rapid cellular differentiation and turnover, such as those in the immune system and gastrointestinal tract. Therapeutic zinc supplementation has been initiated in low-income countries as part of diarrhea treatment programs to support these needs for young children but, the effects of preventive supplemental zinc as a tablet or as a multiple micronutrient powder (MNP) on child growth and diarrheal disease are mixed and pose programmatic

2018 Clinical Trials

162. Efficacy Of Probiotics vs. Zinc vs. Probiotics-Zinc Combination On Acute Diarrhea In Children

Chart" Secondary Outcome Measures : Diarrhea duration [ Time Frame: Till the end of diarrhea, an average of five days ] duration of diarrhea in days Hospital stay [ Time Frame: Till the end of diarrhea, an average of four days ] Length of hospital stay in days Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn (...) of zinc to the standard treatment. The third group will be managed by the addition to a combination of zinc and probiotics to standard treatment. The patients will be followed to compare the effect of the given medication on the duration of diarrhea. Condition or disease Intervention/treatment Phase Acute Diarrhea Other: Probiotics Other: Zinc Other: Probiotics & Zinc Other: Standard care Not Applicable Detailed Description: This is a prospective, randomized, double blinded, clinical trial

2018 Clinical Trials

163. Incidence of Diarrhea Using High and Low Osmolality Enteral Tube Feeding in Critically Ill Surgical Patients

calculation via nasojejunal tube. Active Comparator: Osmolite 1.5 Higher osmolality enteral tube feed formulation Other: Osmolite 1.5 Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube. Outcome Measures Go to Primary Outcome Measures : Incidence of diarrhea at 72 hours [ Time Frame: 72 hour ] Secondary Outcome Measures : Incidence of diarrhea at 14 days [ Time Frame: 14 days ] Mean frequency of diarrhea days [ Time Frame: 14 days ] Total number of diarrhea days (...) of an ileostomy or colostomy History of inflammatory bowel disease, bowel resection, short gut syndrome, or chronic diarrhea Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03487744 Locations Layout table for location information United States, Utah

2018 Clinical Trials

164. A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated Diarrhea

by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF Proportion of subjects taking anti-diarrheal medication [ Time Frame: Up to 4 weeks ] Proportion of subjects taking anti-diarrhoeal medication as recorded in the eCRF Proportion of subjects with AEs and SAEs [ Time Frame: Up to 4 weeks ] Proportion of subjects with AEs and SAEs were assessed from the start of the study until end of study as recorded in the eCRF Other Outcome Measures: Overall Response Rate [ Time Frame: Up to 4 weeks (...) , or dosage reduction. Currently, no prophylactic measure was demonstrated efficaciously. Bacillus cereus is an aerobic spore-forming bacterium that is commonly found in soil. The efficacy of Bacillus cereus in the management of afatinib treatment-associated diarrhoea has not been extensively evaluated in clinical studies. This is a single-arm, single-institutional, phase II study evaluating the efficacy and safety of Bacillus cereus (Changfukang®) in the prevention of afatinib-associated diarrhea

2018 Clinical Trials

165. Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

enterocolitica, Campylobacter jejuni, Salmonella, Shigella, ovum and parasites, and/or Clostridium difficile Subject who has psychiatric disorders which are not controlled ("controlled" is based on the Investigator's medical judgment); subjects with psychoses are excluded regardless of current therapy. Subject has current or recent history (within 12 months before signing informed consent) of drug, laxative or alcohol abuse Subject is pregnant or lactating Subject has a history of human immunodeficiency (...) explore the oral microbiome in IBS patients, and assess its relationship with fecal microbiome between responders and non-responders. Condition or disease Intervention/treatment Phase Irritable Bowel Syndrome With Diarrhea Drug: Rifaximin Oral Tablet Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science

2018 Clinical Trials

166. TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial

diarrhoea (SeHCAT results of > 10% or C4 results of <19 ng/ml), Note: Cholecystectomy will not be an exclusion criteria if bile acid diarrhoea has been excluded Lactose malabsorption. Coeliac disease (tTG or duodenal biopsy) All patients must agree to use methods of medically acceptable forms of contraception during the study and for 90 days after completion of study drug, (e.g. implants, injectable, combined oral contraceptives, True abstinence (when this is in line with the preferred and usual (...) provided by University of Leeds: Diarrhoea Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Ondansetron Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Antipruritics Dermatologic Agents

2018 Clinical Trials

167. Oral Administration of Tannins and Flavonoids vs Sacchaomyces Boulardii in Pediatric Acute Diarrhea

population of children affected by AG in terms of duration of diarrhea Condition or disease Intervention/treatment Phase Diarrhea Acute Gastroenteritis Acute Diarrhea Device: Actitan-F Drug: Saccharomyces Boulardii 250 MG Oral Powder Other: Dicodral 60 Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 160 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary (...) Purpose: Treatment Official Title: A Prospective Randomized-controlled Trial on Efficacy of Oral Administration of Tannins and Flavonoids and Standard Oral Rehydration (SOR) vs Saccharomyces Boulardii and SOR in Treatment of Pediatric Acute Diarrhea Estimated Study Start Date : December 2018 Estimated Primary Completion Date : December 2019 Estimated Study Completion Date : March 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm

2018 Clinical Trials

168. Point-of-Use Pathogen Identification Tool for Diarrhea

. This may make it easier for health care workers to more quickly fight diarrheal diseases. Objective: To test a tool that may detect what germs cause diarrhea. Eligibility: People already enrolled in an active NIH protocol who have diarrhea Design: Participants will have 1 or 2 studies. They will give information about their symptoms, current medicines, and basic personal data. They will give a stool sample. Part of each sample will be tested in a lab. The rest will be stored indefinitely. No personal (...) pathogen testing using the NIH standard of care, BioFire FilmArray GI Pathogen Panel (FDA approved PCR based pathogen diagnostic) by the Department of Laboratory Medicine (DLM) is indicated. Collected stool samples will be tested for pathogens causing GI disease, using the FilmArray GI panel by the DLM. Technicians in the NINR laboratories will test aliquots from the same stool samples using our tool. The tool has been designed for detection of the most common diarrhea causing pathogens. Of primary

2018 Clinical Trials

169. Community Mobilization and Incentivization for Childhood Diarrhea and Pneumonia

Primary Completion Date : July 31, 2020 Estimated Study Completion Date : October 30, 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Community Mobilization This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry (...) : July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Pneumonia Diarrhea Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms, Digestive Signs and Symptoms

2018 Clinical Trials

170. Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes. Other Name: Pepto Bismol Placebo Comparator: Placebo Placebo oral tablet 4 bid Drug: Placebo Oral Tablet Placebo manufactured to mimic pepto bismol Outcome Measures Go to Primary Outcome Measures : Traveler's diarrhea [ Time Frame: Change from baseline through 10 days post-travel ] Self-reported TD Secondary Outcome Measures : Gut AMR genes [ Time Frame: Once within 7 days (before travel); once (...) : Centers for Disease Control and Prevention Collaborators: Procter and Gamble New York Center for Travel and Tropical Medicine Information provided by (Responsible Party): Kristina Angelo, Centers for Disease Control and Prevention Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among

2018 Clinical Trials

171. Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea

Last Update Posted : August 20, 2018 Sponsor: Omnifarma Kiev LLC Information provided by (Responsible Party): Omnifarma Kiev LLC Study Details Study Description Go to Brief Summary: The purpose of the study is to demonstrate the antidiarrheal efficacy of colloidal silicon dioxide in tablet dosage form (Carbowhite) in patients with acute diarrhea. Condition or disease Intervention/treatment Phase Diarrhoea;Acute Drug: Carbowhite Drug: Carbowhite placebo Phase 2 Detailed Description: Background (...) -180 First Posted: August 16, 2018 Last Update Posted: August 20, 2018 Last Verified: August 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Omnifarma Kiev LLC: Diarrhoea Carbowhite Colloidal silicon dioxide Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Signs and Symptoms, Digestive Signs

2018 Clinical Trials

172. Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial. Full Text available with Trip Pro

, up to a maximum of 17 days. The primary outcome will be the incidence of AAD, defined as ≥3 loose or watery stools (a score of A on the Amsterdam Infant Stool Scale or a score of 5-7 on the Bristol Stool Form scale) in 24 hours, caused either by Clostridium difficile or of otherwise unexplained aetiology, occurring during the intervention period. The secondary outcomes will include the incidence of AAD according to alternative definitions; the incidence of any kind of diarrhoea; the duration (...) of diarrhoea; the need for hospitalisation; intravenous rehydration or discontinuation of antibiotic treatment due to diarrhoea; adverse events; and the intestinal microbiota composition.The study protocol is approved by the Ethics Committee of the Medical University of Warsaw. The findings will be published in a peer-reviewed journal and submitted to relevant conferences.14/10/2017.NCT03334604; Pre-results.© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018

2018 BMJ open

173. Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant

Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant (DIETSINIBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03423069 Recruitment Status : Recruiting First Posted : February

2018 Clinical Trials

174. Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

medication to the passage of the last unformed stool (TLUS), in compliance with the relevant guidelines Secondary end-points to determine: The number of patients showing improvement in diarrhoea during a 24-h interval, i.e. >50 % reduction of bowel movements. The number of unformed stools passed per 24-h interval, after dosing. The number of patients who are declared to be "well". Wellness is defined as the patient having 48 hours with no unformed stools, a maximum of two soft stools and no clinical (...) data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS) Secondary Outcome Measures : The Number of Patients Showing Improvement in Diarrhoea During a 48h Interval [ Time Frame: 48 hours ] The evaluation of improvement in diarrhoea during a 48 hour interval is defined as a >50% reduction of bowel movements versus the baseline value The Number of Unformed

2018 Clinical Trials

175. A Study of Colesevelam for Lenalidomide-Associated Diarrhea

. The primary end-point is improvement of diarrhea to grade 1 or better according to the CTCAE 5.0 scale by 4 weeks of treatment with colesevelam. Secondary Outcome Measures : GI symptom assessment [ Time Frame: 4 weeks ] To assess GI symptoms using Patient Reported Outcomes within the Common Terminology Criteria for Adverse Events Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) with serum triglyceride levels >300 mg/dL Patients wit history of hypertriglyceridemia-induced panreatitis Patients with known hypersensitivity to colesevelam or any component to the formulation Patients currently already receiving a bile acid sequestrant or have previously used bile acid sequestrant drugs for diarrhea and had no benefit Patients with diarrhea secondary to infection. Infections will need to be ruled out (Clostridium difficile PCR when clinically indicated, GI pathogen panel, stool ova

2018 Clinical Trials

176. Pathogenesis of microscopic colitis: a systematic review on intestinal luminal factors, autoimmunity, innate and adaptative immunity, extracellular matrix remodelling, genetic risk factors and the mechanism of diarrhoea

Pathogenesis of microscopic colitis: a systematic review on intestinal luminal factors, autoimmunity, innate and adaptative immunity, extracellular matrix remodelling, genetic risk factors and the mechanism of diarrhoea Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete (...) screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text

2020 PROSPERO

177. Berberine for diarrhea: a systematic review and meta-analysis

Berberine for diarrhea: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr (...) . No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we

2020 PROSPERO

178. Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics (R61)

of the study product Has telephone access Exclusion Criteria: Any chronic condition, such as diabetes or asthma, that requires medication Allergy to strawberry Active diarrhea (three or more loose stools per day for two consecutive days) Any gastrointestinal medications, i.e. medicines for irritable bowel syndrome, gastroesophageal reflux disease, inflammatory bowel disease, etc. (a full medication list will be reviewed by the PIs prior to enrollment) History of heart disease, including valvulopathies (...) effects of antibiotic medications. One of the most common indications for probiotics is for prevention of antibiotic-associated diarrhea. Clinically, different probiotic strains have demonstrated the ability to prevent AAD; however, the mechanism of action behind this effect has not been elucidated. Data from several studies suggest that antibiotic-induced disruption of commensal bacteria in the colon results in a significant (up to 50%) reduction in short chain fatty acid (SCFA) production

2018 Clinical Trials

179. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

, should be accompanied by cognitive-behavioral therapies whenever possible. Short/intermediate acting benzodiazepine receptor agonists (benzodiazepines [BZDs] or newer BZD receptor agonistic modulators [BzRAs]) or ramelteon were recommended as first-line pharmacotherapy. Other drugs, such as sedating antidepressants or anticonvulsant medications were recommended as second- or third-line agents, particularly when comorbidities (e.g. mood disorder or epilepsy) are present. Other, non-prescription drugs (...) impairment), and work-related accidents. General treatment measures for insomnia include the treatment of comorbid medical and psychiatric conditions, modifying sleep-interfering medications and substances, and optimizing the sleep environment. Specific treatments for insomnia fall into two primary categories. Non-pharmacological therapies, largely cognitive behavioral in nature, have been the subject of numerous meta-analyses and practice guidelines. , – Pharmacological therapy, including over

2017 American Academy of Sleep Medicine

180. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.

: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. Study Start Date : December 2014 Actual Primary Completion Date : December 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment (...) . Outcome Measures Go to Primary Outcome Measures : Efficacy measured by the decrease in the intensity of diarrhea and / or anti-diarrheal consumption [ Time Frame: 1 month ] Effectiveness of acetylsalicylic acid versus diosmectite Secondary Outcome Measures : Toxicity [ Time Frame: Three months ] Diarrhea decrease 3 months after the introduction of acetylsalicylic acid or diosmectite; Proportion of patients with a decrease in the grade of diarrhea during the months following the introduction

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>